ContraVir Pharmaceuticals Inc Share Price Nasdaq
Equities
US21234W1036
Biotechnology & Medical Research
Sales 2022 | - | Sales 2023 | - | Capitalization | 14.05M 1.17B |
---|---|---|---|---|---|
Net income 2022 | -42M -3.51B | Net income 2023 | -48M -4.01B | EV / Sales 2022 | - |
Net cash position 2022 | 51.14M 4.27B | Net cash position 2023 | 14.58M 1.22B | EV / Sales 2023 | - |
P/E ratio 2022 |
-0.5
x | P/E ratio 2023 |
-0.26
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 99.89% |
Managers | Title | Age | Since |
---|---|---|---|
John Cavan
CEO | Chief Executive Officer | 65 | 01/16/01 |
Daren Ure
CTO | Chief Tech/Sci/R&D Officer | - | 03/19/03 |
Stephen Kilmer
IRC | Investor Relations Contact | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
John Brancaccio
CHM | Chairman | 76 | 15/13/15 |
Timothy Block
BRD | Director/Board Member | 69 | 26/13/26 |
Kaouthar Lbiati
BRD | Director/Board Member | 45 | 27/22/27 |
1st Jan change | Capi. | |
---|---|---|
+16.61% | 122B | |
+17.75% | 112B | |
+17.23% | 25.91B | |
-24.11% | 19.33B | |
-18.56% | 16.17B | |
-18.47% | 15.6B | |
-47.75% | 14.65B | |
+57.35% | 14.34B | |
+5.62% | 14B |